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Abstract
Background: Major haemoptysis occurs in approximately 1% of children with cystic fibrosis (CF). This report describes
management and follow-up of these children at a tertiary centre in Australia. Methods: Retrospective review of medical records
from 1980–1999. Results: Fifty-one children (45% female) had major haemoptysis (102 episodes). Mean age at first episode was
15 years (range 7–19) and mean FEV was 56% predicted (range 14–98). Massive life-threatening haemoptysis was not confined1
to those with severe lung disease (FEV -50% predicted). Bronchial artery embolisation (BAE) was more likely to be the initial1
treatment for those with massive haemoptysis and chronic recurrent bleeding tended to be treated conservatively (Ps0.01).
Overall, 52 BAE were performed in 28 children with an immediate success rate of 98%; 13 children (46%) had repeated BAE.
Four patients died as a direct result of severe haemoptysis. Mean follow-up was 54 months (range 0.5–183). Median survival
time (Kaplan–Meier estimate) after first haemoptysis was 70 months, with a significantly longer survival for male patients
independent of age (RR 3.8; 95% CI 1.7–8.8; Ps0.001). Median survival time following initial treatment with BAE was longer
(103 months) compared to conservative treatment (52 months, Ps0.09). Conclusions: Massive haemoptysis was unrelated to the
severity of lung disease and was more likely to be treated with embolisation. BAE was highly effective, however, 46% of the
children required re-embolisation at some time, which is similar to the recurrence risk for major hemoptysis treated conservatively
on longer term follow-up.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Haemoptysis is uncommon in the paediatric popula-
tion, however, it is a potentially life-threatening condi-
tion w1,2x. With the decreasing incidence of tuberculosis
and bronchiectasis, cystic fibrosis (CF) has become the
principal cause of major haemoptysis in older children
and young adults in developed countries w3,4x. Episodes
Abbreviations: ATS, American Thoracic Society; BAE, Bronchial
artery embolisation; CF, Cystic fibrosis; CI, Confidence interval;
FEV , Forced expiratory volume in 1 s; FVC, Forced vital capacity;1
IPPV, Intermittent positive pressure ventilation; MRSA, Multi resis-
tant staphylococcus aureus; RCH, Royal Children’s Hospital; RR,
Relative risk.
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of minor bleeding (blood streaking) are common and
have been reported in up to 60% of patients with CF
over 18 years of age w5x. Major haemoptysis occurs in
approximately 1% of all patients with CF and is more
frequent as their disease progresses. It is rarely seen in
children younger than 10 years and occurs up to 1.5%
in the age group of 16–20 years w6x.
The generally used definition of major haemoptysis,
however, arbitrary, is acute bleeding of more than 240
mlyday or recurrent bleeding of substantial volumes ()
100 mlyday) over a few days or weeks w7–9x. Chronic
or recurrent, small haemoptysis (-100 mlyday) inter-
fering with patients lifestyle (e.g. sporting activities)
andyor preventing effective physiotherapy or home man-
agement is also considered by some to represent a
significant haemoptysis w9,10x. Haemoptysis in CF is
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believed to result from erosion of enlarged, thin walled,
tortuous and newly developed abnormal bronchial ves-
sels found in areas of bronchiectasis secondary to
chronic infection w11–14x.
There are several reported approaches to the manage-
ment of haemoptysis in children and young adults with
CFw7x. Minor haemoptysis (blood streaked sputum)
usually requires no specific treatment. In many patients
with major haemoptysis, the bleeding stops spontane-
ously within a few days. At times, conservative treat-
ment (e.g. bedrest, intensive IV antibiotics, vitamin K,
blood replacement, temporary discontinuation of positive
pressure chest physiotherapy) is sufficient to control the
symptoms w11x. There are two case reports published
about the use of a tranexamic acid w15,16x, an antifibri-
nolytic agent (lysine analogue), in the treatment of
major haemoptysis in children with CF including one
from our clinic w16x.
Percutaneous bronchial artery embolisation (BAE)
has been shown to be a safe and effective method of
controlling haemoptysis in both CF w9,10,12,14,17–20x
and non-CF populations w21,22x. No controlled studies
have been conducted examining its superiority over
conservative therapy in reducing long-term rate of major
haemoptysis and in improving patient’s survival w20x.
Rarely, when severe pulmonary bleeding fails to respond
to medical treatment and BAE, surgical intervention,
e.g. bronchial artery ligation or local pulmonary resec-
tion may be necessary w8,23–25x.
This report describes our experience in the manage-
ment and long-term follow up of children with CF and
major haemoptysis at the Royal Children’s Hospital in
Melbourne, Australia, from 1980 to 1999.
2. Methods
In the last 20 years, the CF Unit at the Royal
Children’s Hospital has managed the care of approxi-
mately 750 children with CF. By the end of 1999 there
were approximately 340 children at the CF Unit. This
represents over 90% of the children in the state of
Victoria with a diagnosis of CF. Until 1989, the diag-
nosis of CF was made on the basis of clinical presen-
tation and a positive sweat test w26x. Neonatal screening
was introduced in Victoria in March 1989. We retro-
spectively reviewed all available medical records with
the discharge diagnosis of haemoptysis and CF from
January 1980 to December 1999.
Haemoptysis was considered to be major and by
inference, clinically relevant, on the basis of following
criteria: (1) massive haemoptysis as a single event ()
250 mlyday), (2) recurrent bleeding of substantial vol-
ume ()100 mlyday) over a few days or (3) recurrent
or chronic small haemoptysis (-100 ml) interfering
with patient’s lifestyle (e.g. sporting activities) andyor
preventing effective physiotherapy or home management
w9x. Children with minor bleeding (blood streaked spu-
tum) were excluded.
Lung function tests (FVC and FEV ) were obtained1
from the laboratory database. All lung function had been
obtained by a trained respiratory technician using ATS
criteria for paediatric lung function testing w27x. CF lung
disease was classified into mild (FEV )75% predicted),1
moderate (FEV 50–75% predicted) and severe1
(FEV -50% predicted).1
Sputum culture and sensitivity results were obtained
from the medical records. Multi-resistant strains were
defined as resistant to G2 classes of antibiotics: Ami-
noglycosides (tobramycin, gentamicin), third-generation
cephalosporins (ceftazidime), penicillins (ticarcillin with
clavulanic acid), quinolones (ciprofloxacin), polymyx-
ins (colistin) andyor monobactams (aztreonam).
Prior to 1985 all BAE were performed in an adjacent
adult hospital, thereafter the majority were performed at
the RCH. The embolic material used was polyvinyl
alcohol (Ivalon , Pacific Medical Industries, La Mesa,
California) containing particles ranging in size from 150
to 550 mm, gelatin pledgets (Gelfoam , Upjohn, Kala-
mazoo) andyor Gianturco coils (Cook). As a routine
the descending thoracic aorta and intercostal arteries
were examined for bronchial arteries by a femoral artery
catheter. Vessels that were enlarged andyor abnormally
tortuous were embolised. If catheter placement could
not be secured, embolisation was not performed. The
presence of spinal artery circulation arising from a
bronchial artery was a relative contraindication or abso-
lute if the origin was distal to the catheter tip. A
postembolisation angiogram was usually obtained. BAE
was considered successful if the patient’s haemoptysis
stopped or significantly reduced. If significant haemo-
ptysis persisted or recurred, the procedure was repeated
and considered as a separate procedure in the results.
Statistical analysis was performed using Stata 6.0.
Survival curves were estimated using the Kaplan–Meier
method and crude comparisons between groups per-
formed with the log-rank test. The proportional hazards
regression model was used to estimate hazard ratios or
relative risks adjusted for potential confounding effects.
3. Results
Fifty-one patients with cystic fibrosis had major hae-
moptysis over the last 20 years (approx. 6% of all CF
patients). There were a total of 102 significant bleeding
episodes with a mean of two episodes per child (range
1–7). Twenty-three (45%) were female and 28 (55%)
were male. Age at first bleeding ranged from 7 to 19
years (mean age 15 years), however, only 4 children
(8%) were younger than 10 years. Males were older
(mean age 16.2 years) compared to the females (mean
age 13.5 years). Twelve patients (24%) had a massive
bleeding ()240 ml) and four of them presented with
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Table 1
Severity of lung disease and type of bleeding at presentation
Severity of lung disease Type of bleeding Total
Massive Moderate Chronic recurrent
FEV -50%1 3 4 15 22 (43%)
FEV 50–75%1 7 2 7 16 (31%)
FEV )75%1 2 7 4 13 (26%)
Total 12 (24%) 13 (25%) 26 (51%) 51 (100%)
Fig. 1. Conservative management as initial treatment.
pulmonary haemorrhage of greater than 500 ml of blood
loss in 24 h. Mean FEV at first haemoptysis was 56%1
predicted (range: 14–98). Massive life-threatening hae-
moptysis was not confined to those with severe lung
disease (FEV -50% predicted), however, 58% of the1
children with chronic recurrent bleeding had severe lung
disease (Table 1).
Resistant mucoid Pseudomonas aeruginosa, was
grown in the sputum of 24 (47%) children, 15 (29%)
had a sensitive mucoid Pseudomonas aeruginosa and
six (12%) had a resistant rough Pseudomonas aerugi-
nosa combined with a sensitive mucoid Pseudomonas
aeruginosa. Only two children (4%) had a methicillin
Staphylococcus aureus (MRSA). Burkholderia cepacia
was not identified in any of the children.
The first episode of haemoptysis was conservatively
treated in 29 patients (57%) and 22 patients (43%) had
an embolisation as first treatment (Figs. 1 and 2). The
majority of massive bleeding was treated by embolisa-
tion (83%) and chronic recurrent haemoptysis tended to
be treated conservatively (81%) (Table 2). A total of
52 embolisations were performed in 28 children. Six
children had an embolisation following initial conser-
vative treatment due to recurrence of bleeding after an
average time of 27.3 months (median 19.5, range 3–
67). The immediate success rate after BAE defined as
no recurrent bleeding within 24 h was 98%. Thirteen
children required more than one BAE (re-embolisation
rate 46%) with a median time between first and second
embolisation of 4 months (mean 18.9, range: 5 days–
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Table 2
Type of bleeding and initial treatment at presentation
Type of bleeding Initial treatment
Conservative Embolisation
Massive 2 10
Moderate 6 7
Chronic recurrent 21 5
Total 29 (57%) 22 (43%)
Fig. 2. Embolisation as initial treatment.
83 months). Three children required 3, one 4 and two
5 embolisations.
Two patients had angiography but BAE was not
performed because the catheter could not be safely
placed in the bronchial arteries. The majority (89%) of
BAE was performed using polyvinyl alcohol (Ivalon ).
Gelatin pledgets (Gelfoam ) were only used in few
procedures as well as Gianturco coils. At our institution
a coil has not been used since 1988 as their use has
been found to hamper further embolisation in the distri-
bution of vessels that have been previously coiled. In
two patients bleeding could not be controlled by BAE
and lobectomy was performed, one because of massive
pulmonary haemorrhage ()1 l) and the other because
of a persistent bleeding despite three embolisations as a
result of multiple aberrant bronchial arteries w16x.
A bronchoscopy to localise and identify the specific
site of haemorrhage was only performed on four occa-
sions (4%) out of 102 bleeding episodes.
Four patients died as a consequence of severe hae-
moptysis. One died as a result of a fatal pulmonary
haemorrhage during anaesthetic induction for BAE and
two children died soon after a massive haemoptysis
during anaesthetic induction for BAE, which has been
reported elsewhere w28x. The fourth patient was initially
managed conservatively but required embolisation for
major bleeding 42 months after initial haemoptysis. He
had a fatal haemoptysis 10 months later.
The median survival time in the whole group (Kap-
lan–Meier estimate) was 70 months with significantly
greater survival in males than females (relative risks
3.8; 95% confidence interval 1.7–8.8; Ps0.001 by log-
rank test) (Fig. 3). Rates of embolisation treatment were
identical between the sexes (43% each). There was a
weak evidence of improved survival time following
initial treatment with BAE (103 months) vs. conserva-
tive treatment (52 months), which was not statistically
significant by log-rank test (Ps0.09) (Fig. 4). After
adjustment for the potential confounding effect of dif-
ferences in sex—severity of initial lung disease and
bleeding type between the conservatively treated and
embolisation group—the estimated treatment difference
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Fig. 3. Kaplan–Meier survival estimates, by sex (95% pointwise confidence band shown).
Fig. 4. Kaplan–Meier survival estimates, by initial treatment (95% pointwise confidence band shown).
was little changed (RRs0.47; 95% CI 0.16–1.38; Ps
0.17). In this regression model, the sex difference
remained large (RRs3.0; 95% CI 1.2–7.4), while
amongst the three bleeding types, the lowest mortality
was in the moderate category (RRs0.35; 95% CI 0.1–
1.2 compared to the severe group).
4. Discussion
This retrospective study describes the longest follow
up of children with CF and major haemoptysis in the
literature. BAE was highly effective as well as more
likely to be used in patients with massive haemoptysis.
However, 46% of the children required re-embolisation
at some time, which is similar to the recurrence risk for
major hemoptysis treated conservatively on longer term
follow-up and is slightly higher than the reported re-
embolisation rate in other published studies (Table 3).
In 1970, Holscaw et al. w3x published a survival study
of 19 CF-patients with severe haemoptysis and described
a mortality rate of 32% after the first episode. All
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Table 3
Studies on bronchial artery embolisation in patients with CF
Study No. Age (range) Follow-up Re-embolisation
(years) (month) (%)
Fellows et al. (1979) 13 7–24 11 (1–30) 31
Sweezy et al. (1990) 25 7–35 35 (1–101) 36
Cohen et al. (1990) 19 6–43 34 (7–62) 42
Tonkin et al. (1991) 11 7–36 42 (4–96) 45
Cipolli et al. (1995) 14 15–39 15 (0.5–38) 21
Present study 28 7–19 54 (0.5–183) 46
patients were conservatively treated. Six of the 13
survivors had recurrent haemoptysis (recurrence rate of
46%) and another 7 patients died within 6 months. A
few years later, Stern et al. w11x reported an average
survival time of 2.5 years (range: 3 months–6 years) in
38 CF-patients with conservatively treated massive hae-
moptysis. This figure was not significantly different
from matched controls (equally severe lung disease)
without haemoptysis. The reported recurrence rate was
45%. Twenty-six percent of the CF-patients with major
haemoptysis died during the study period, however, no
patient died as a direct result of haemoptysis.
BAE was first reported by Remy and colleagues in
1974 w17x. Since then, many reports have been published
describing this technique including its use in patients
with CF w9,10,12,19,20x. BAE is an effective method
for controlling haemoptysis in cystic fibrosis with a
reported immediate success rate up to 96% w22x. In our
hospital, catheter embolisation of bronchial arteries was
first used for our patients in 1980. In the early years,
the policy was more in favour of conservative treatment,
however, interventional procedures were favoured in the
latter years.
The re-embolisation rate of our patients of 46% was
similar to other published studies (Table 3). Fellows et
al. w12x reported 13 patients with severe haemorrhage
treated by BAE with a follow-up of an average 11
months. Their immediate success rate was 62%. Four
patients (31%) required repeat embolisations within 10
days and 5 patients (38%) had recurrent minor haemop-
tysis. Sweezy and Fellows w19x studied the long-term
outcome after BAE of 25 CF-patients with massive
haemoptysis with an average follow-up of 35 months.
Nine patients had a repeated BAE (re-embolisation rate
of 36%, interval between 5 days and 24 months).
Twenty-four percent of the 25 patients died within three
month of BAE (in two of them haemoptysis was a
contributing cause) and the mean survival of the survi-
vors (remaining 19 patients) was 3.5 years. The re-
embolisation rate reported by Cohen et al. w10x was
42% in 19 patients with CF. Cipolli et al. w20x had a
low re-embolisation rate of 21% in 14 CF-patients,
however, his average follow-up was only 15 months. In
the latter report, 50% were free of major haemoptysis
one year after BAE. The longest reported follow-up to
date is by Tonkin et al. w9x who describes a re-
embolisation rate of 45% that is very similar to ours.
The superiority of BAE over conservative therapy in
reducing the long-term recurrence rate of massive hae-
moptysis and improving the survival time has not yet
been proven w20x. In our data there was a trend towards
reduced mortality in those initially treated with embol-
isation (after adjustment for sex and severity differenc-
es), but the confidence interval around this estimate was
very wide, indicating the need for larger samples to
make definite conclusions. In addition, our study was
not a direct comparison of conservative treatment vs.
embolisation as there was neither randomisation to each
group nor clear clinical indications for inclusion in
either group.
In our study, 3 children died following massive
pulmonary haemorrhage during anaesthesia for BAE,
which is described in detail elsewhere w28x. It is believed
that factors associated with intermittent positive pressure
ventilation (IPPV) were important in precipitating these
bleedings. Other possible explanations for rebleeding,
such as hypertension due to inadequate anaesthesia at
intubation and laryngoscopy, or bronchial artery vaso-
dilatation seem less likely. As a result of these events
the practice of anaesthesia for BAE at the RCH was
changed to a combination of intravenous sedation and
local anaesthesia whenever possible, thus avoiding the
use of IPPV.
Major haemoptysis in CF is believed to occur in those
patients with diffuse severe lung disease w3x. In our
study we did not find any relationship between massive
haemoptysis and the severity of lung disease (FEV ),1
however, the majority of children with chronic recurrent
bleeding had severe lung disease. Severe bleeding can
also be associated with mild disease w29x, possibly
arising in a localised area of more severe inflammation
or as a result of multiple aberrant arteries w16x. This
emphasises the need to identify each of the bronchial
arteries and to search for any aberrant arteries by an
aortogram before performing selective catheterisation
and embolisation of all abnormal bronchial vessels w10x.
In patients with major haemoptysis as a life threat-
ening event, the first priority is to maintain the airway,
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optimise oxygenation and stabilise the hemodynamic
status followed by BAE or surgical intervention w30x.
At our institution, BAE is always considered if there is
a massive or moderate bleeding. However, chronic or
recurrent haemoptysis interfering with patient’s lifestyle
andyor preventing effective physiotherapy is usually
treated conservatively before considering BAE. While
some patients will settle with conservative treatment,
BAE should always be considered earlier than later if
conservative treatment fails.
In summary, this retrospective study has demonstrated
that massive haemoptysis is unrelated to the severity of
lung disease and was more likely to be treated with
embolisation. Despite its efficiency, the superiority of
BAE over conservative therapy in reducing recurrent
bleeding and long-term mortality remains unproven.
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